abrdn Physical Palladium Shares ETF vs uniQure N.V. Ordinary Shares — how do they compare? abrdn Physical Palladium Shares ETF trades at $20.43 (market cap $602.28M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 2.4× abrdn Physical Palladium Shares ETF's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 34 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PALL | QURE | |
|---|---|---|
Market Cap | $602.28M | $1.45B |
Volume | 980,533 | 3,323,243 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $70.59 |
52-Week Low | $19.83 | $9.03 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
PALL trades at $20.38, down 1.12% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while palladium prices remain 47% below January 2026 highs. Recent news highlights potential catch-up opportunities as platinum and palladium have lagged the broader precious metals rally.
The outlook suggests contrarian opportunity as palladium approaches technical support levels, though fundamental data remains limited. Key risks include continued commodity price pressure and industrial demand uncertainty, while potential catalysts include supply constraints and renewed institutional interest in undervalued precious metals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →